Message #2 From:
NewsBot Date: January 22, 2006 07:16:42 PM
HBSC Human Biosystems Inc., Stock Message Board, News, DD, Quote
Breaking News: Human BioSystems Continues Platelet Testing at Second Independent Laboratory
Human BioSystems (OTCBB:HBSC message board, news, quote, dd), developer of preservation platforms for organs and other biomaterials, announces today that it plans to commence blood platelet testing at a second independent laboratory under a research agreement signed in June, 2005.
This agreement calls for the laboratory to assist the Company in testing its methods and protocols for extending the storage of blood platelets. The goal is to confirm in-vitro (test tube) results obtained by HBS in conjunction with another independent laboratory, and then to proceed to human infusion studies. "We decided to enlist a second laboratory to conduct the same tests in order to give us greater confidence in our results," said Dr. Winter, President of Human BioSystems. Testing is scheduled to start in January 2006.
The first independent laboratory contracted by HBS has recently completed the in-vitro test phase and is now preparing to proceed to human infusion studies, pending further internal and FDA approvals that may be required before starting the tests. "We are pleased with the in-vitro results from the first laboratory and are anxious to see the results of the infusion studies," noted Dr. Winter.
Blood platelets are the clotting component of blood and are collected from donors and infused into cancer patients that have undergone chemotherapy and/or radiation treatments. Such treatments inhibit the production of platelets for a period of time which can result in bleeding without regular platelet infusion.
"Currently, platelets have an FDA mandated 5 day shelf life. It is our goal to extend the shelf life by utilizing the proprietary HBS solution and process to preserve platelets at refrigerated temperatures for at least 7 or more days," said Dr. Winter.
"We believe that if our technology is successful and brought to market it would drastically reduce the outdating of platelets, allowing blood centers to significantly reduce their costs. We also believe that refrigeration will inhibit bacteria growth, resulting in a safer product," added Harry Masuda, CEO of Human BioSystems.
Breaking News: Human BioSystems Confirms Earlier Organ Preservation Survival Test Results-Now Seeks Strategic Partner
Human BioSystems (OTCBB:HBSC), developer of preservation platforms for organs and other biomaterials, announces today that it has confirmed the results announced in the press release of October 19, 2005 by doubling the total sample size used in the initial survival study of animals with transplanted kidneys preserved using the Company's HBS Above Zero Organ Preservation (HBS-AZ) Solution. In comparison to kidneys stored in a solution presently considered the medical gold standard in Europe (and quickly gaining acceptance in the U.S.) named the "HTK" solution, the HBS-AZ solution exhibited significantly better results.
"In the cumulative results of the survival studies, we continued to have 80% of the rats with kidneys preserved in the HBS-AZ solution survive for more than seven days, whereas only 10% of the same number of rats with kidneys preserved in the HTK solution survived more than seven days," said Dr. Fernando Lopez, HBS Senior Research Scientist.
"There is a statistical significance to the results obtained and our HBS-AZ preservation solution is significantly better than the HTK solution in this study," said Dr. Luis Toledo, HBS Chief Medical Officer.
Dr. David Winter, HBS President, stated that "there are over 40,000 organ transplants performed in the world each year and more than 90,000 people are on the waiting list in the U.S. alone that need a new organ, according to UNOS (United Network for Organ Sharing). Because of the acute shortage of available donor organs, improvements in preservation time and quality of the preserved organ should serve to further optimize the available organ pool by increasing the percentage of successful transplants."
Dr. Winter further stated that "We are now actively seeking a strategic partner that would participate with HBS to obtain FDA approval and to market our HBS-AZ preservation solution to hospitals and organ procurement organizations throughout the world."
Breaking News: Human BioSystems Breaks New Ground-Successfully Transplants Kidney Frozen for 3 Months
Human BioSystems (OTCBB:HBSC) announces today that it was successful in transplanting a rat kidney that had been frozen at a temperature of -80 degreesC for three months in the patent pending HBS Sub-Zero Solution.
"While today's organ preservation technology limits preservation times to only hours, Human BioSystems was able to freeze a rat kidney for 3 months, preserved in the HBS Sub-Zero Solution," stated Dr. Luis Toledo, HBS Chief Medical Officer. "After warming the organ to room temperature the kidney was transplanted into the animal, producing urine for one hour before the animal was sacrificed for further histological tests," continued Dr. Toledo.
The Reperfusion Index (RPI), developed by HBS to indicate a kidney's viability, measured an RPI index score of 14 out of 15 possible in this case, an almost perfect organ. "The excellent RPI score was possible in part because the kidney was able to produce urine even after being frozen for 3 months, which in our opinion is quite remarkable and unprecedented," said Dr. Toledo.
"In order to overcome the damaging effects of freezing, HBS scientists had to limit the expansion of ice to a small fraction of what normally occurs when water freezes. Since the kidney consists primarily of water, this became a very important consideration when freezing an organ," according to Dr. Toledo. "We also had to avoid the harmful effects of crystallization when water turns to ice," Dr. Toledo commented. He further stated that "Both problems were essentially addressed by developing a proprietary solution that not only limits the expansion of water when it turns to ice, but also inhibits the normal crystal formation pattern of ice when the organ is frozen, thereby protecting most of the cells from the damaging effects of the freezing process."
"The results obtained in this experiment show that it is possible to freeze a complex organ such as a kidney for an extended period of time and still maintain its functional characteristics when thawed and transplanted," said Dr. David Winter, HBS President.
Dr. Winter went on to say that "Once human donor organs become more widely available for transplantation, freezing might become a means to bank organs for future use or to allow the time necessary to more optimally match a donor's organ to the recipient. A better donor/recipient match could reduce the need for anti-rejection drugs, which are costly and can be detrimental to the organ recipient over the long term," concluded Dr. Winter.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the ability of the Company to fund marketing and sales efforts that may be required to effectively sell its products, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Human BioSystems (OTC Bulletin Board:HBSC)
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
OR
YES INTERNATIONAL
Rich Kaiser
Investor Relations
(800) 631-8127
yes@yesinternational.com
